Coreline Soft said that it would supply AVIEW LCS PLUS, an artificial intelligence-based solution for diagnosing chest diseases, to St. Mary Hospital, in Yilan County, Taiwan.

Coreline Soft will supply its AI chest solution, AVIEW LCS PLUS, to St. Mary Hospital, a Taiwanese hospital.
Coreline Soft will supply its AI chest solution, AVIEW LCS PLUS, to St. Mary Hospital, a Taiwanese hospital.

AVIEW LCS PLUS is a device that automatically analyzes and quantifies the image data obtained from a single chest computed tomography (CT) scan and provides information about lung cancer and cardiovascular diseases at the same time. The device can also increase work speed and accuracy in various areas, such as disease analysis and diagnosis through AI, treatment plans, and detailed reports.

"Significantly, one of the largest hospitals in the Yilan County placed the first order for AVIEW LCS PLUS, which simultaneously diagnoses related diseases mainly in the lungs, expanding sales channel," Coreline Soft overseas business director, Suh Jung-hyeok said. “By turning orders from regional hospitals into a bridgehead, we will do our best to quickly secure a sales network in the region and expand it to all regions of Taiwan."

Coreline Soft is active in lung cancer screening.

Since 2017, the company has provided a diagnostic solution for Korea's national lung cancer screening for five consecutive years, with about 90 medical institutions, including the National Cancer Center, using its products for lung cancer screening.

The company has also been introducing its product overseas, centering on major advanced countries, and is participating in various lung cancer screening projects, such as the 4-IN-THE-LUNG-RUN (4ITLR) project conducted in six European countries for four years and the Holistic Implementation Study Assessing a Northern German Interdisciplinary Lung Cancer Screening Effort (HANSE) led by the University of Hannover in Germany.

Most recently, the company finalized a contract to supply its AI chest diagnosis solution to INTM and a lung cancer screening project (ILSP), participated in by 18 Italian hospitals, the company said. The project will go on for a year across Italy from 2022.

Copyright © KBR Unauthorized reproduction, redistribution prohibited